Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials.
about
Nail Psoriasis: A Review of Treatment OptionsThe influence of innate and adaptive immune responses on atherosclerosisLong-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvementImpact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials.Preclinical development of AMG 139, a human antibody specifically targeting IL-23Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients.Association between Psoriasis Vulgaris and Coronary Heart Disease in a Hospital-Based Population in Japan.The Role of IL-17 and Th17 Lymphocytes in Autoimmune DiseasesAdaptive immunity in atherogenesis: new insights and therapeutic approaches.Association of ustekinumab and briakinumab with major adverse cardiovascular events: An appraisal of meta-analyses and industry sponsored pooled analyses to dateAntipsoriatic treatment extends beyond the skin: recovering of high-density lipoprotein functionCombined biologic therapy for the treatment of psoriasis and psoriatic arthritis: A case report.Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting.Relationship between tumor necrosis factor-α inhibitors and cardiovascular disease in psoriasis: a review.Sequential use of biologics in moderate-to-severe plaque psoriasis: case studies illustrating an individualized approach.Reporting of meta-analyses of randomized controlled trials with a focus on drug safety: an empirical assessment.Burden of disease: psoriasis and psoriatic arthritis.Biological therapies for psoriasis.Phototherapy, psoriasis, and the age of biologics.Ustekinumab: moving the target from psoriasis to Crohn's disease.Does treatment of psoriasis reduce the risk of cardiovascular disease?Systemic therapies for psoriasis: an evidence-based update.Ustekinumab : targeting the IL-17 pathway to improve outcomes in psoriatic arthritis.Apremilast for the treatment of psoriatic arthritis.Adverse reactions to biologic agents and their medical management.IL-17RA in intestinal inflammation: structure, signaling, function, and clinical application.Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity.Myocardial infarction in a patient treated with anti-interleukin-12 biological agent for chronic plaque psoriasis.Efficacy and safety of emerging immunotherapies in psoriasis.Novel systemic therapies for the treatment of psoriasis.Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders.Inflammatory cytokines in atherosclerosis: current therapeutic approaches.A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases.The safety of ustekinumab for the treatment of psoriatic arthritis.Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?Recent Advances in Small Molecule and Biological Therapeutic Approaches in the Treatment of Psoriasis.The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis.
P2860
Q26753038-0A739182-60FA-4997-8337-97CAC26A520AQ27000370-931F341F-F53A-474E-89E7-62D546C34F78Q30574065-F922D609-192A-4DA2-89AF-E54F2DA277C1Q30577671-C0FAD59B-7FE4-476B-8C9D-54E4B9F7F640Q30620977-A411389D-9663-4F0B-A707-E4566F478D63Q33625546-C20D9637-5529-4AD2-9710-980F2D9876D5Q34795742-4D8540BE-6B4B-43E9-8C51-9765FCE16318Q35606402-4C1A9823-4CCE-4068-A0BC-6AC4DFCF72F5Q35860158-E13C3391-BC5A-4533-82A2-035C15D9D984Q35934076-1591A3FA-42A0-4BBE-8C8E-CC67A9CA781CQ36249305-D5B07C14-BB71-42CC-B93C-66C340995D91Q36497196-8A2EB809-9564-440B-B134-FDAF8E2BC54DQ36643600-7AA0D73B-12D5-401E-805F-2D2707A63929Q36681220-FBDF476A-2461-4F1C-8871-8DA2580F50DAQ36714257-C0DD2D34-728F-40DD-84CD-3D86C6985D79Q37258726-2D0B9E98-A598-48F4-8844-D1B53C708412Q37632485-46D6AB37-859E-4433-A272-C351E1974A2CQ38053456-57A8CE17-FDCA-43C2-877B-242E557C1542Q38091030-D4360462-A88A-44C5-BFDB-C0C2A53E3BE2Q38114850-D48E82CB-0945-463F-8474-251C34611395Q38155648-F4760E92-A653-439A-81DD-C5AB0ADF1C6EQ38169210-A28939DF-7123-42FD-8A40-A79204392F9DQ38177321-D9663855-5EFB-415E-BF67-EB43CA827365Q38178202-851D4C55-9124-476C-AE2F-FC3D1B9E7140Q38185297-709811F3-AD0A-4A13-9101-371B98AFE856Q38189853-E3D77F3D-8937-4919-BCD1-A81184D72410Q38202205-CDC9050C-947C-4A47-916D-E213CEB13705Q38238948-40C290D0-665A-45B6-A18F-A8B8B7762213Q38255855-186E0AEE-7EF1-4739-9462-934AB5261F66Q38264660-FB6BF054-CEE9-40E7-AB58-0D60EB19563EQ38303098-78D90CF9-E56F-4CC7-B33E-449386E530F4Q38365042-8C0937B4-CC38-43B6-87BB-AE5E3A9178B8Q38628193-F567E55F-5BE4-45FE-8B22-279EF3DFA3B0Q38632657-A3FBA3F0-0D21-4CD7-81E5-6E3D861D41A3Q38722298-98FADFD2-D0C3-4336-937C-BF4FEAC118DDQ38749257-592D6FD2-7EF8-4FFB-8EE8-C47EACA030E7Q38820480-C09F4BA2-2344-4EE5-AB5A-573C42C5076CQ38836998-2BDB8A38-7C3A-47FF-AA58-94FAEF87DC43Q38895147-95100A7B-643A-4FD3-B7FE-6460B55804CDQ39064616-B1ED153C-4E45-4CDF-A3C4-8D7DA374CCEE
P2860
Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Re-evaluation of the risk for ...... randomized controlled trials.
@ast
Re-evaluation of the risk for ...... randomized controlled trials.
@en
Re-evaluation of the risk for ...... randomized controlled trials.
@nl
type
label
Re-evaluation of the risk for ...... randomized controlled trials.
@ast
Re-evaluation of the risk for ...... randomized controlled trials.
@en
Re-evaluation of the risk for ...... randomized controlled trials.
@nl
prefLabel
Re-evaluation of the risk for ...... randomized controlled trials.
@ast
Re-evaluation of the risk for ...... randomized controlled trials.
@en
Re-evaluation of the risk for ...... randomized controlled trials.
@nl
P2093
P2860
P921
P1476
Re-evaluation of the risk for ...... randomized controlled trials.
@en
P2093
A Kyrgidis
C C Zouboulis
P2860
P304
P356
10.1111/J.1468-3083.2012.04500.X
P577
2012-03-08T00:00:00Z